Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21425191 | 0.91 | CA14 (0.38) | CA14HDAC6L3MBTL1HDAC1HDAC2 | |
| SCHEMBL15694959 | 0.91 | CA14 (0.38) | CA14HDAC6L3MBTL1HDAC1HDAC2 | |
| SCHEMBL25247476 | 0.90 | CA14 (0.41) | CA14HDAC6L3MBTL1HDAC1HDAC2 | |
| SCHEMBL20055158 | 0.88 | CA14 (0.36) | CA14HDAC6L3MBTL1HDAC1HDAC2 | |
| SCHEMBL16967933 | 0.87 | CA14 (0.37) | CA14HDAC6L3MBTL1 | |
| SCHEMBL16893294 | 0.87 | CA14 (0.35) | CA14HDAC6L3MBTL1ALDH1A1 | |
| SCHEMBL24840513 | 0.87 | CA14 (0.35) | CA14HDAC6L3MBTL1HDAC1HDAC2 | |
| SCHEMBL24447239 | 0.85 | CA14 (0.35) | CA14HDAC6L3MBTL1 | |
| SCHEMBL6538686 | 0.85 | HDAC6 (0.37) | CA14HDAC6HDAC1HDAC2ALDH1A1 | |
| SCHEMBL2526136 | 0.85 | HDAC6 (0.39) | CA14HDAC6L3MBTL1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10155777-B2 | Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling | UNIVERSITY OF DELAWARE (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180072761-A1 | TRANS-CYCLOHEPTENES AND HETERO-TRANS-CYCLOHEPTENES FOR BIOORTHOGONAL COUPLING | UNIVERSITY OF DELAWARE (US) | 2018-03-15 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| WO-2016164565-A1 | TRANS-CYCLOHEPTENES AND HETERO-TRANS-CYCLOHEPTENES FOR BIOORTHOGONAL COUPLING | UNIVERSITY OF DELAWARE (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | CA14 4385/4885HDAC6 1349/4885L3MBTL1 3692/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | CA14 4461/4885HDAC6 1387/4885L3MBTL1 3627/4885 |
| US-10155777-B2 | Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling | HCRTR2, HCRTR1, CRHR2 | CA14 3182/4885HDAC6 1956/4885L3MBTL1 2230/4885 |
| US-20180072761-A1 | TRANS-CYCLOHEPTENES AND HETERO-TRANS-CYCLOHEPTENES FOR BIOORTHOGONAL COUPLING | HCRTR2, HCRTR1, CRHR2 | CA14 3182/4885HDAC6 1956/4885L3MBTL1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.